31hP |
رقم الكتالوجGC92375
One-Click Copy Product Info
|
31hP is an ionizable cationic lipid (pKa = 6.25) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and single-guide RNA (sgRNA) in vitro and in vivo.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
31hP is an ionizable cationic lipid (pKa = 6.25) that has been used in the generation of lipid nanoparticles (LNPs) for the delivery of mRNA and single-guide RNA (sgRNA) in vitro and in vivo. Intravenous administration of LNPs containing 31hP and encapsulating mRNA encoding Cas9 and sgRNA targeting transtretin (TTR) reduce serum TTR levels in mice to a greater extent than those containing DLin-MC3-DMA . Intramuscular administration of LNPs containing 31hP and encapsulating mRNA encoding severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein increases serum antibody titers in mice to a greater extent than those containing SM-102 .
| Cas No. | SDF | ||
| Chemical Name | undecan-3-yl 4-(1-((2-(diethylamino)ethyl)(methyl)amino)-7-(heptadecan-9-yloxy)-7-oxohept-2-yn-1-yl)benzoate | ||
| Canonical SMILES | CCN(CC)CCN(C)C(C#CCCCC(OC(CCCCCCCC)CCCCCCCC)=O)C1=CC=C(C(OC(CC)CCCCCCCC)=O)C=C1 | ||
| Formula | C49H86N2O4 | M.Wt | 767.237 |
| الذوبان | Ethanol: Soluble: ≥10 mg/ml | Storage | -20°C |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.3034 mL | 6.5169 mL | 13.0338 mL |
| 5 mM | 260.7 μL | 1.3034 mL | 2.6068 mL |
| 10 mM | 130.3 μL | 651.7 μL | 1.3034 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solution in ethanol
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)